Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ivosidenib + mFOLFIRINOX in Resectable Pancreatic Adenocarcinoma
NCT05209074Phase 1Active, not recruiting
- Sponsor
- Case Comprehensive Cancer Center
- Start
- Sep 2022
- Primary completion
- Jul 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of ivosidenib in pancreatic ductal adenocarcinoma (PDAC), sponsored by Case Comprehensive Cancer Center. Primary endpoint: Maximum-tolerated dose or Recommended Phase 2 dose at 24 months. Started Sep 2022; status: active, not recruiting.
02
Drugs
ivosidenib
03
Conditions
pancreatic ductal adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NCT05209074.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05209074.